Effects of combination therapy with montelukast and carbocysteine in allergen-induced airway hyperresponsiveness and airway inflammation

K. Takeda, Y. Shiraishi, S. Matsubara, Nobuaki Miyahara, H. Matsuda, M. Okamoto, A. Joetham, E. W. Gelfand

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background and purpose: Montelukast and S-carbocysteine have been used in asthmatic patients as an anti-inflammatory or mucolytic agent respectively. S-carbocysteine also exhibits anti-inflammatory properties. Experimental approach: Ovalbumin (OVA) sensitized BALB/c mice were challenged with OVA for 3 days followed by single OVA re-challenge (secondary challenge) 2 weeks later. Forty-eight hours after secondary challenge, mice were assessed for airway hyperresponsiveness (AHR) and cell composition in bronchoalveolar lavage (BAL) fluid. Suboptimal doses of 10 mg·kg-1 of S-carbocysteine by intraperitoneal injection (ip), 20 mg·kg-1 of montelukast by gavage, the combination of S-carbocysteine and montelukast or 3 mg·kg-1 of dexamethasone as a control were administered from 1 day before the secondary challenge to the last experimental day. Isolated lung cells were cultured with OVA and montelukast to determine the effects on cytokine production. Key results: Treatment with S-carbocysteine or montelukast reduced both AHR and the numbers of eosinophils in BAL fluid. Neutralizing IFN-γ abolished the effects of S-carbocysteine on these airway responses. Combination of the two drugs showed further decreases in both AHR and eosinophils in the BAL fluid. Goblet cell metaplasia and Th2-type cytokines, interleukin (IL)-4, IL-5 and IL-13, in BAL fluid were decreased with montelukast treatment. Conversely, S-carbocysteine increased Th1-type cytokines, IFN-γ and IL-12 in BAL fluid. Conclusions and inplications: The combination of two agents, montelukast and S-carbocysteine, demonstrated additive effects on AHR and airway inflammation in a secondary allergen model most likely through independent mechanisms of action.

Original languageEnglish
Pages (from-to)1399-1407
Number of pages9
JournalBritish Journal of Pharmacology
Volume160
Issue number6
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

montelukast
Carbocysteine
Allergens
Bronchoalveolar Lavage Fluid
Inflammation
Ovalbumin
Therapeutics
Cytokines
Eosinophils
Anti-Inflammatory Agents
Expectorants
Goblet Cells
Interleukin-13
Interleukin-5
Metaplasia
Drug Combinations
Interleukin-12
Intraperitoneal Injections
Interleukin-4

Keywords

  • airway hyperresponsiveness
  • carbocysteine
  • eosinophils
  • montelukast
  • neutrophils

ASJC Scopus subject areas

  • Pharmacology
  • Medicine(all)

Cite this

Effects of combination therapy with montelukast and carbocysteine in allergen-induced airway hyperresponsiveness and airway inflammation. / Takeda, K.; Shiraishi, Y.; Matsubara, S.; Miyahara, Nobuaki; Matsuda, H.; Okamoto, M.; Joetham, A.; Gelfand, E. W.

In: British Journal of Pharmacology, Vol. 160, No. 6, 2010, p. 1399-1407.

Research output: Contribution to journalArticle

Takeda, K. ; Shiraishi, Y. ; Matsubara, S. ; Miyahara, Nobuaki ; Matsuda, H. ; Okamoto, M. ; Joetham, A. ; Gelfand, E. W. / Effects of combination therapy with montelukast and carbocysteine in allergen-induced airway hyperresponsiveness and airway inflammation. In: British Journal of Pharmacology. 2010 ; Vol. 160, No. 6. pp. 1399-1407.
@article{b7d9a585f7ce44e79e685d3544ed1906,
title = "Effects of combination therapy with montelukast and carbocysteine in allergen-induced airway hyperresponsiveness and airway inflammation",
abstract = "Background and purpose: Montelukast and S-carbocysteine have been used in asthmatic patients as an anti-inflammatory or mucolytic agent respectively. S-carbocysteine also exhibits anti-inflammatory properties. Experimental approach: Ovalbumin (OVA) sensitized BALB/c mice were challenged with OVA for 3 days followed by single OVA re-challenge (secondary challenge) 2 weeks later. Forty-eight hours after secondary challenge, mice were assessed for airway hyperresponsiveness (AHR) and cell composition in bronchoalveolar lavage (BAL) fluid. Suboptimal doses of 10 mg·kg-1 of S-carbocysteine by intraperitoneal injection (ip), 20 mg·kg-1 of montelukast by gavage, the combination of S-carbocysteine and montelukast or 3 mg·kg-1 of dexamethasone as a control were administered from 1 day before the secondary challenge to the last experimental day. Isolated lung cells were cultured with OVA and montelukast to determine the effects on cytokine production. Key results: Treatment with S-carbocysteine or montelukast reduced both AHR and the numbers of eosinophils in BAL fluid. Neutralizing IFN-γ abolished the effects of S-carbocysteine on these airway responses. Combination of the two drugs showed further decreases in both AHR and eosinophils in the BAL fluid. Goblet cell metaplasia and Th2-type cytokines, interleukin (IL)-4, IL-5 and IL-13, in BAL fluid were decreased with montelukast treatment. Conversely, S-carbocysteine increased Th1-type cytokines, IFN-γ and IL-12 in BAL fluid. Conclusions and inplications: The combination of two agents, montelukast and S-carbocysteine, demonstrated additive effects on AHR and airway inflammation in a secondary allergen model most likely through independent mechanisms of action.",
keywords = "airway hyperresponsiveness, carbocysteine, eosinophils, montelukast, neutrophils",
author = "K. Takeda and Y. Shiraishi and S. Matsubara and Nobuaki Miyahara and H. Matsuda and M. Okamoto and A. Joetham and Gelfand, {E. W.}",
year = "2010",
doi = "10.1111/j.1476-5381.2010.00797.x",
language = "English",
volume = "160",
pages = "1399--1407",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Effects of combination therapy with montelukast and carbocysteine in allergen-induced airway hyperresponsiveness and airway inflammation

AU - Takeda, K.

AU - Shiraishi, Y.

AU - Matsubara, S.

AU - Miyahara, Nobuaki

AU - Matsuda, H.

AU - Okamoto, M.

AU - Joetham, A.

AU - Gelfand, E. W.

PY - 2010

Y1 - 2010

N2 - Background and purpose: Montelukast and S-carbocysteine have been used in asthmatic patients as an anti-inflammatory or mucolytic agent respectively. S-carbocysteine also exhibits anti-inflammatory properties. Experimental approach: Ovalbumin (OVA) sensitized BALB/c mice were challenged with OVA for 3 days followed by single OVA re-challenge (secondary challenge) 2 weeks later. Forty-eight hours after secondary challenge, mice were assessed for airway hyperresponsiveness (AHR) and cell composition in bronchoalveolar lavage (BAL) fluid. Suboptimal doses of 10 mg·kg-1 of S-carbocysteine by intraperitoneal injection (ip), 20 mg·kg-1 of montelukast by gavage, the combination of S-carbocysteine and montelukast or 3 mg·kg-1 of dexamethasone as a control were administered from 1 day before the secondary challenge to the last experimental day. Isolated lung cells were cultured with OVA and montelukast to determine the effects on cytokine production. Key results: Treatment with S-carbocysteine or montelukast reduced both AHR and the numbers of eosinophils in BAL fluid. Neutralizing IFN-γ abolished the effects of S-carbocysteine on these airway responses. Combination of the two drugs showed further decreases in both AHR and eosinophils in the BAL fluid. Goblet cell metaplasia and Th2-type cytokines, interleukin (IL)-4, IL-5 and IL-13, in BAL fluid were decreased with montelukast treatment. Conversely, S-carbocysteine increased Th1-type cytokines, IFN-γ and IL-12 in BAL fluid. Conclusions and inplications: The combination of two agents, montelukast and S-carbocysteine, demonstrated additive effects on AHR and airway inflammation in a secondary allergen model most likely through independent mechanisms of action.

AB - Background and purpose: Montelukast and S-carbocysteine have been used in asthmatic patients as an anti-inflammatory or mucolytic agent respectively. S-carbocysteine also exhibits anti-inflammatory properties. Experimental approach: Ovalbumin (OVA) sensitized BALB/c mice were challenged with OVA for 3 days followed by single OVA re-challenge (secondary challenge) 2 weeks later. Forty-eight hours after secondary challenge, mice were assessed for airway hyperresponsiveness (AHR) and cell composition in bronchoalveolar lavage (BAL) fluid. Suboptimal doses of 10 mg·kg-1 of S-carbocysteine by intraperitoneal injection (ip), 20 mg·kg-1 of montelukast by gavage, the combination of S-carbocysteine and montelukast or 3 mg·kg-1 of dexamethasone as a control were administered from 1 day before the secondary challenge to the last experimental day. Isolated lung cells were cultured with OVA and montelukast to determine the effects on cytokine production. Key results: Treatment with S-carbocysteine or montelukast reduced both AHR and the numbers of eosinophils in BAL fluid. Neutralizing IFN-γ abolished the effects of S-carbocysteine on these airway responses. Combination of the two drugs showed further decreases in both AHR and eosinophils in the BAL fluid. Goblet cell metaplasia and Th2-type cytokines, interleukin (IL)-4, IL-5 and IL-13, in BAL fluid were decreased with montelukast treatment. Conversely, S-carbocysteine increased Th1-type cytokines, IFN-γ and IL-12 in BAL fluid. Conclusions and inplications: The combination of two agents, montelukast and S-carbocysteine, demonstrated additive effects on AHR and airway inflammation in a secondary allergen model most likely through independent mechanisms of action.

KW - airway hyperresponsiveness

KW - carbocysteine

KW - eosinophils

KW - montelukast

KW - neutrophils

UR - http://www.scopus.com/inward/record.url?scp=77954075135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954075135&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2010.00797.x

DO - 10.1111/j.1476-5381.2010.00797.x

M3 - Article

C2 - 20590630

AN - SCOPUS:77954075135

VL - 160

SP - 1399

EP - 1407

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 6

ER -